Share this article

The US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for ANP Technologies’ NIDS COVID-19 Antigen Rapid Test Kit.

The test is a lateral flow immunoassay (LFA) that is developed using ANP’s Nano-Intelligent Detection System (NIDS) platform technology for the detection of SARS-CoV-2 from direct nasal swabs using NIDS Swab Buffer.

It uses highly sensitive antibodies for the detection of the SARS-CoV-2 nucleocapsid protein in nasal swab specimens.

ANP chief technology officer and president Ray Yin said: “The NIDS COVID-19 Antigen Rapid Test was developed using our NIDS technology platform that was initially developed for the rapid detection of various biological warfare agents for the US military more than a decade ago.

“With the Covid-19 pandemic, ANP quickly configured its NIDS platform for the detection of SARS-CoV-2 antigen and achieved outstanding performance under the funding from the Department of Defense and the RADx initiative.”

The NIDS COVID-19 Antigen Rapid Test Kit provides a visual result in 15 minutes based on the presence or absence of pink/purple-coloured lines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The company stated that the test is also effective in the detection of many other Covid-19 variants, including Delta.

ANP business development and contracts senior director Greg Whitham said: “With this pivotal FDA authorisation, ANP is now focusing on the large-scale production of the test kits and welcomes all partnerships and collaborations to improve testing production capacity and speed to market, which is paramount to get folks back to work/school and reopen the economy.”

The NIDS test is authorised for use at the point of care and does not differentiate between SARS-CoV and SARS-CoV-2.